Subject: Press Release/News Attached for Distribution on Stockwatch.com
PDF Document
File: Attachment 20240726_BIOV_NR_Upsizing of Private Placement.pdf
BIOVAXYS ANNOUNCES UPSIZING OF PRIVATE PLACEMENT
// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES //
VANCOUVER, BC, July 26, 2024 - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys"
or the "Company") is pleased to announce an increase to its previously announced non-brokered private
placement offering of units of the Company ("Units") at a price of $0.05 per Unit (the "Private
Placement"). Each Unit consists of one common share (a "Common Share") and one whole Common
Share purchase warrant (a "Warrant"), whereby each Warrant is exercisable for one additional Common
Share at an exercise price of $0.15 for a period of 24 months. The Private Placement initially comprised
10,000,000 Units (see news release dated July 23, 2024) for total gross proceeds of CAD $500,000. The
Company has now increased the size of the Private Placement to up to 20,000,000 Units for total gross
proceeds of up to CAD $1,000,000.
Closing of the Private Placement is subject to receipt of all necessary regulatory and other approvals. All
securities to be issued pursuant to the Private Placement will be subject to a statutory hold period of four
months and one day from the date of issuance.
The Company intends to use the net proceeds of the Private Placement for general working capital purposes,
including enabling the Company to fund and advance its business plans in regard to its successful recent
acquisition of the entire portfolio of discovery, preclinical and clinical development stage assets in
oncology, infectious disease, antigen desensitization, and other immunological fields based on the DPXTM
immune educating platform technology, developed by the former Canadian biotechnology company, IMV
Inc., Immunovaccine Technologies Inc., which was purchased from IMV USA ("IMV") on February 16,
2024. The Company may pay finder's fees in connection with the Private Placement.
In addition, the Company announces that, further to its news release of July 23, 2024, it has increased the
amount of debt it intends to settle by an additional $40,000. The Company plan to fully settle up to a
maximum of CAD $773,600 in debt through the issuance of up to a maximum of 15,472,000 Common
Shares at a deemed price of $0.05 per Common Share. The board of directors of the Company has
determined that it is in the best interests of the Company to settle the outstanding debts by the issuance of
Common Shares in order to preserve the Company's cash for working capital. The debt settlement is
expected to include the participation of certain related parties including, BioVaxys CEO and director, James
Passin, BioVaxys COO and President Kenneth Kovan, BioVaxys directors Anthony Dutton and Craig
Loverock and BioVaxys consultant Loverock Consulting Corp., and, as such, will constitute a "related party
transaction" within the meaning of Multilateral Instrument 61-101 Protection of Minority Security
Holders in Special Transactions ("MI 61-101"). The Company is relying on the exemptions from the
valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(a) and
5.7(1)(a) of MI 61-101, as the fair market value of the shares for debt transaction with the forgoing related
parties does not exceed 25% of the market capitalization of the Company, as determined in accordance with
MI 61-101.
All securities proposed to be issued in connection with the Debt Settlement will be subject to a statutory
hold period of four months plus a day from the date of issuance in accordance with applicable securities
legislation. Closing of the Debt Settlement is conditional upon a number of conditions, including finalizing
all contractual documentation and receipt of all applicable regulatory approvals and the policies of the
Canadian Securities Exchange.
The securities described herein have not been, and will not be, registered under the United States Securities
Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws, and may not be offered
or sold within the United States except in compliance with the registration requirements of the U.S.
Securities Act and applicable state securities laws or pursuant to available exemptions therefrom. This
release does not constitute an offer to sell or a solicitation of an offer to buy of any securities in the United
States.
About BioVaxys Technology Corp.
BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British
Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with
novel immunotherapies based on the DPXTM immune-educating technology platform and it's HapTenixcopyright
`neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization,
and other immunological fields. The Company's clinical stage pipeline includes maveropepimut-S which
is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma
(DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic
vaccine using its' proprietary HapTenixcopyright `neoantigen' tumor cell construct platform which is soon to enter
Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its
tumor immunology knowhow and creation of a unique library of T-lymphocytes & other datasets post-
vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other
technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the Canadian
Securities Exchange under the stock symbol "BIOV", on the Frankfurt Bourse (FRA: 5LB), and quoted in
the US on the OTC Markets (OTCQB: BVAXF). For more information, visit www.biovaxys.com and
connect with us on X and LinkedIn.
ON BEHALF OF THE BOARD
Signed "James Passin"
James Passin, Chief Executive Officer
Phone: +1 646 452 7054
Cautionary Statements Regarding Forward Looking Information
The Canadian Securities Exchange ("CSE") has neither approved nor disapproved the contents of this
press release. The CSE does not accept responsibility for the adequacy or accuracy of this release. This
press release includes certain "forward-looking information" and "forward-looking statements"
(collectively "forward-looking statements") within the meaning of applicable Canadian and United States
securities legislation including the United States Private Securities Litigation Reform Act of 1995. All
statements, other than statements of historical fact, included herein, without limitation, statements relating
the future operating or financial performance of the Company, are forward looking statements. Forward-
looking statements are frequently, but not always, identified by words such as "expects", "anticipates",
"believes", "intends", "estimates", "potential", "possible", and similar expressions, or statements that
events, conditions, or results "will", "may", "could", or "should" occur or be achieved. There can be no
assurance that such statements will prove to be accurate, and actual results and future events could differ
materially from those expressed or implied in such forward-looking statements.
These forward-looking statements reflect the beliefs, opinions and projections on the date the statements
are made and are based upon a number of assumptions and estimates, primarily the assumption that
BioVaxys will be successful in developing and testing vaccines, that, while considered reasonable by the
Company, are inherently subject to significant business, economic, competitive, political and social
uncertainties and contingencies including, primarily but without limitation, the risk that BioVaxys'vaccines
will not prove to be effective and/ or will not receive the required regulatory approvals. With regards to
BioVaxys' business, there are a number of risks that could affect the development of its biotechnology
products, including, without limitation, the need for additional capital to fund clinical trials, its lack of
operating history, uncertainty about whether its products will complete the long, complex and expensive
clinical trial and regulatory approval process for approval of new drugs necessary for marketing approval,
uncertainty about whether its autologous cell vaccine immunotherapy can be developed to produce safe
and effective products and, if so, whether its vaccine products will be commercially accepted and profitable,
the expenses, delays and uncertainties and complications typically encountered by development stage
biopharmaceutical businesses, financial and development obligations under license arrangements in order
to protect its rights to its products and technologies, obtaining and protecting new intellectual property
rights and avoiding infringement to third parties and their dependence on manufacturing by third parties.
The Company does not assume any obligation to update the forward-looking statements of beliefs, opinions,
projections, or other factors, should they change, except as required by law.
© 2024 Canjex Publishing Ltd. All rights reserved.